MedPath

Vortioxetine

Generic Name
Vortioxetine
Brand Names
Brintellix, Trintellix
Drug Type
Small Molecule
Chemical Formula
C18H22N2S
CAS Number
508233-74-7
Unique Ingredient Identifier
3O2K1S3WQV
Background

Vortioxetine is an antidepressant medication indicated for the treatment of major depressive disorder (MDD). It is classified as a serotonin modulator and stimulator (SMS) as it has a multimodal mechanism of action towards the serotonin neurotransmitter system whereby it simultaneously modulates one or more serotonin receptors and inhibits the reuptake of serotonin. More specifically, vortioxetine acts via the following biological mechanisms: as a serotonin reuptake inhibitor (SRI) through inhibition of the serotonin transporter, as a partial agonist of the 5-HT1B receptor, an agonist of 5-HT1A, and an antagonist of the 5-HT3, 5-HT1D, and 5-HT7 receptors. SMSs were developed because there are many different subtypes of serotonin receptors, however, not all of these receptors appear to be involved in the antidepressant effects of SRIs. Some serotonin receptors seem to play a relatively neutral or insignificant role in the regulation of mood, but others, such as 5-HT1A autoreceptors and 5-HT7 receptors, appear to play an oppositional role in the efficacy of SRIs in treating depression.

Indication

用于治疗重度抑郁症成人患者。

Associated Conditions
Major Depressive Disorder (MDD)

Vortioxetine for Depressive Symptoms and Freezing of Gait in Parkinson Disease

Phase 4
Not yet recruiting
Conditions
Parkinson Disease, Idiopathic
Freezing of Gait
Depression Not Otherwise Specified
Interventions
First Posted Date
2025-02-03
Last Posted Date
2025-02-06
Lead Sponsor
Marianna Amboni
Target Recruit Count
40
Registration Number
NCT06805266

Vortioxetine for the Treatment of Mood and Cognitive Symptoms in Frontotemporal Dementia

Phase 2
Recruiting
Conditions
Fronto-temporal Dementia
Fronto-temporal Lobar Dementia
Frontotemporal Degeneration
Frontotemporal Dementia (FTD)
Frontotemporal Dementia, Behavioral Variant
Frontotemporal Dementia
Interventions
First Posted Date
2024-09-19
Last Posted Date
2025-04-02
Lead Sponsor
Johns Hopkins University
Target Recruit Count
50
Registration Number
NCT06604520
Locations
🇺🇸

The Johns Hopkins Hospital, Baltimore, Maryland, United States

Postoperative Pain Management Following Laparoscopic Cholecystectomy

Phase 3
Recruiting
Conditions
Postoperative Pain
Interventions
First Posted Date
2024-08-20
Last Posted Date
2025-01-10
Lead Sponsor
Future University in Egypt
Target Recruit Count
86
Registration Number
NCT06561438
Locations
🇪🇬

National Hepatology and Tropical Research Institute, Cairo, Egypt

Comparison of Vortioxetine Versus Other Antidepressants With Pregabalin Augmentation in Burning Mouth Syndrome

First Posted Date
2023-09-06
Last Posted Date
2023-09-06
Lead Sponsor
Federico II University
Target Recruit Count
203
Registration Number
NCT06025474
Locations
🇮🇹

University of Naples Federico II, Napoli, Italia, Italy

A Database Survey of Comparison The Risk of Haemorrhage Between Vortioxetine Tablet Treatment and Selective Serotonin Reuptake Inhibitor (SSRI) Treatment in Participants With Depression

Completed
Conditions
Major Depressive Disorder
Interventions
First Posted Date
2023-07-06
Last Posted Date
2025-03-03
Lead Sponsor
Takeda
Target Recruit Count
147777
Registration Number
NCT05932407
Locations
🇯🇵

Takeda Selected Site, Tokyo, Japan

Using 18F-FPEB PET to Identify mGLUR5 Availability in Affective Disorders

Recruiting
Conditions
Major Depressive Disorder
Bipolar Disorder
Interventions
First Posted Date
2023-05-03
Last Posted Date
2023-08-14
Lead Sponsor
Central South University
Target Recruit Count
59
Registration Number
NCT05840861
Locations
🇨🇳

Mental Health Institute & Faculty of Psychiatry of The Second Xiangya Hospital, Central South University, Changsha, Hunan, China

Sequenced Treatment Alternatives to Relieve Adolescent Depression (STAR-AD)

First Posted Date
2023-04-18
Last Posted Date
2023-08-14
Lead Sponsor
First Affiliated Hospital of Chongqing Medical University
Target Recruit Count
520
Registration Number
NCT05814640
Locations
🇨🇳

The First Affiliated Hospital of Chongqing Medical University, Chongqing, Province, China

Vortioxetine Adjunctive Treatment in Bipolar Depression

Phase 4
Completed
Conditions
Bipolar Depression
Interventions
Drug: valprote
First Posted Date
2022-08-01
Last Posted Date
2023-09-14
Lead Sponsor
First Affiliated Hospital of Zhejiang University
Target Recruit Count
131
Registration Number
NCT05481957
Locations
🇨🇳

Department of Psychiatry, First Affiliated Hospital of Zhejiang University, Hangzhou, Zhejiang, China

Single Dose Oral Bioequivalence Study of Vortioxetine Hemihydrobromide Orally Disintegrating Tablets

Phase 1
Completed
Conditions
Major Depressive Disorder (MDD)
Interventions
First Posted Date
2022-06-14
Last Posted Date
2023-04-13
Lead Sponsor
Seasons Biotechnology (Taizhou) Co., Ltd.
Target Recruit Count
48
Registration Number
NCT05417087
Locations
🇮🇳

Cliantha Research Limited, Ahmedabad, Gujarat, India

Food Effect Bioavailability Study of Vortioxetine Hemihydrobromide Orally Disintegrating Tablets

Phase 1
Completed
Conditions
Major Depressive Disorder (MDD)
Interventions
First Posted Date
2022-06-14
Last Posted Date
2023-04-13
Lead Sponsor
Seasons Biotechnology (Taizhou) Co., Ltd.
Target Recruit Count
24
Registration Number
NCT05416957
Locations
🇮🇳

Cliantha Research Limited, Ahmedabad, Gujarat, India

© Copyright 2025. All Rights Reserved by MedPath